Alzheimer disease: Amyloid-β immunotherapy CAD106 passes first safety test in patients with Alzheimer disease

摘要

The immunotherapy CAD 106, which comprises the N-terminal of amyloid-beta (Abeta) peptide, has recently completed a double-blind placebo-controlled phase I trial in patients with Alzheimer disease. The drug was found to be safe and to generate an Abeta-specific antibody response, paving the way to future efficacy studies. A previous phase II trial of another Abeta-targeted immunotherapy, AN1792, was suspended early as the treatment caused meningioencephalitis in 6% of treated patients.